lobbying_activities: 1189598

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1189598	b476da5c-8124-4f0f-a39a-88b89b940420	Q4	APOTEX CORP.	310973	APOTEX CORP.	2011	fourth_quarter	PHA	S. 27, the Preserve Access to Affordable Pharmaceuticals Act S. 1882, the FAIR Generics Act S. 296, HR 2245, The Preserving Access to Life Savings Medications Act Amending Section 505(j) of the Food, Drug, and Cosmetic Act, concerning the ability of generic pharmaceutical manufacturers to file counterclams seeking the correction of incorrect information submitted to FDA's Orange Book by patent owners or holders of New Drug Applications Supreme Court consideration of Novo Nordisk A/S and Novo Nordisk Inc. vs Caraco Pharmaceutical Laboratories Ltd. and Sub Pharmaceuticals Industries, Ltd. Prospective action on legislation establishing a generic drug user fee program Prospective action on legislation establishing a biosimilar user fee program Establishment of a federal track and trace system for pharmaceuticals Importation of prescription narcotic products into the United States The use of Risk Evaluation Mitigation Strategies (REMS) programs by brand drug companies to delay generic competition	Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE		110000	0	0	2012-01-18T09:54:02-05:00